Two different extreme ways in R&D of listed pharmaceutical companies, more than 20% of Hanmi against 0.1% of Daihan Pharm

While some pharmaceutical companies have invested more than 20% of sales in R&D (research and development), there are also pharmaceutical companies spending so less in R&D that the expenses cannot even be called as R&D expenses; thus, the industry criticized that R&D investments of pharmaceutical companies have taken two different extreme ways.

According to the YakupDotCom’s analysis result of...